Treatment of Cognitive Disability in Schizophrenia With a GABA-A Alpha2/3 Receptor Agonist.
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2011
At a glance
- Drugs MK 0777 (Primary)
- Indications Cognition disorders; Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- 15 Oct 2011 Actual end date (January 2008) added as reported by ClinicalTrials.gov.
- 15 Oct 2011 Primary endpoint identified as Continuous Performance Test as reported by ClinicalTrials.gov.
- 30 Mar 2009 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History